Cargando…

Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps

Animal models provide useful information on mechanisms in human disease conditions, but also on exploring (patho)physiological factors affecting pharmacokinetics, safety, and efficacy of drugs in development. Also, in pediatric patients, nonclinical data can be critical for better understanding the...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroe, Marina-Stefania, Van Bockstal, Lieselotte, Valenzuela, Allan, Ayuso, Miriam, Leys, Karen, Annaert, Pieter, Carpentier, Sebastien, Smits, Anne, Allegaert, Karel, Zeltner, Adrian, Mulder, Antonius, Van Ginneken, Chris, Van Cruchten, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195037/
https://www.ncbi.nlm.nih.gov/pubmed/37215599
http://dx.doi.org/10.3389/fped.2023.1163100
_version_ 1785044143059238912
author Stroe, Marina-Stefania
Van Bockstal, Lieselotte
Valenzuela, Allan
Ayuso, Miriam
Leys, Karen
Annaert, Pieter
Carpentier, Sebastien
Smits, Anne
Allegaert, Karel
Zeltner, Adrian
Mulder, Antonius
Van Ginneken, Chris
Van Cruchten, Steven
author_facet Stroe, Marina-Stefania
Van Bockstal, Lieselotte
Valenzuela, Allan
Ayuso, Miriam
Leys, Karen
Annaert, Pieter
Carpentier, Sebastien
Smits, Anne
Allegaert, Karel
Zeltner, Adrian
Mulder, Antonius
Van Ginneken, Chris
Van Cruchten, Steven
author_sort Stroe, Marina-Stefania
collection PubMed
description Animal models provide useful information on mechanisms in human disease conditions, but also on exploring (patho)physiological factors affecting pharmacokinetics, safety, and efficacy of drugs in development. Also, in pediatric patients, nonclinical data can be critical for better understanding the disease conditions and developing new drug therapies in this age category. For perinatal asphyxia (PA), a condition defined by oxygen deprivation in the perinatal period and possibly resulting in hypoxic ischemic encephalopathy (HIE) or even death, therapeutic hypothermia (TH) together with symptomatic drug therapy, is the standard approach to reduce death and permanent brain damage in these patients. The impact of the systemic hypoxia during PA and/or TH on drug disposition is largely unknown and an animal model can provide useful information on these covariates that cannot be assessed separately in patients. The conventional pig is proven to be a good translational model for PA, but pharmaceutical companies do not use it to develop new drug therapies. As the Göttingen Minipig is the commonly used pig strain in nonclinical drug development, the aim of this project was to develop this animal model for dose precision in PA. This experiment consisted of the instrumentation of 24 healthy male Göttingen Minipigs, within 24 h of partus, weighing approximately 600 g, to allow the mechanical ventilation and the multiple vascular catheters inserted for maintenance infusion, drug administration and blood sampling. After premedication and induction of anesthesia, an experimental protocol of hypoxia was performed, by decreasing the inspiratory oxygen fraction (FiO(2)) at 15%, using nitrogen gas. Blood gas analysis was used as an essential tool to evaluate oxygenation and to determine the duration of the systemic hypoxic insult to approximately 1 h. The human clinical situation was mimicked for the first 24 h after birth in case of PA, by administering four compounds (midazolam, phenobarbital, topiramate and fentanyl), frequently used in a neonatal intensive care unit (NICU). This project aimed to develop the first neonatal Göttingen Minipig model for dose precision in PA, allowing to separately study the effect of systemic hypoxia versus TH on drug disposition. Furthermore, this study showed that several techniques that were thought to be challenging or even impossible in these very small animals, such as endotracheal intubation and catheterization of several veins, are feasible by trained personnel. This is relevant information for laboratories using the neonatal Göttingen Minipig for other disease conditions or drug safety testing.
format Online
Article
Text
id pubmed-10195037
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101950372023-05-19 Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps Stroe, Marina-Stefania Van Bockstal, Lieselotte Valenzuela, Allan Ayuso, Miriam Leys, Karen Annaert, Pieter Carpentier, Sebastien Smits, Anne Allegaert, Karel Zeltner, Adrian Mulder, Antonius Van Ginneken, Chris Van Cruchten, Steven Front Pediatr Pediatrics Animal models provide useful information on mechanisms in human disease conditions, but also on exploring (patho)physiological factors affecting pharmacokinetics, safety, and efficacy of drugs in development. Also, in pediatric patients, nonclinical data can be critical for better understanding the disease conditions and developing new drug therapies in this age category. For perinatal asphyxia (PA), a condition defined by oxygen deprivation in the perinatal period and possibly resulting in hypoxic ischemic encephalopathy (HIE) or even death, therapeutic hypothermia (TH) together with symptomatic drug therapy, is the standard approach to reduce death and permanent brain damage in these patients. The impact of the systemic hypoxia during PA and/or TH on drug disposition is largely unknown and an animal model can provide useful information on these covariates that cannot be assessed separately in patients. The conventional pig is proven to be a good translational model for PA, but pharmaceutical companies do not use it to develop new drug therapies. As the Göttingen Minipig is the commonly used pig strain in nonclinical drug development, the aim of this project was to develop this animal model for dose precision in PA. This experiment consisted of the instrumentation of 24 healthy male Göttingen Minipigs, within 24 h of partus, weighing approximately 600 g, to allow the mechanical ventilation and the multiple vascular catheters inserted for maintenance infusion, drug administration and blood sampling. After premedication and induction of anesthesia, an experimental protocol of hypoxia was performed, by decreasing the inspiratory oxygen fraction (FiO(2)) at 15%, using nitrogen gas. Blood gas analysis was used as an essential tool to evaluate oxygenation and to determine the duration of the systemic hypoxic insult to approximately 1 h. The human clinical situation was mimicked for the first 24 h after birth in case of PA, by administering four compounds (midazolam, phenobarbital, topiramate and fentanyl), frequently used in a neonatal intensive care unit (NICU). This project aimed to develop the first neonatal Göttingen Minipig model for dose precision in PA, allowing to separately study the effect of systemic hypoxia versus TH on drug disposition. Furthermore, this study showed that several techniques that were thought to be challenging or even impossible in these very small animals, such as endotracheal intubation and catheterization of several veins, are feasible by trained personnel. This is relevant information for laboratories using the neonatal Göttingen Minipig for other disease conditions or drug safety testing. Frontiers Media S.A. 2023-05-04 /pmc/articles/PMC10195037/ /pubmed/37215599 http://dx.doi.org/10.3389/fped.2023.1163100 Text en © 2023 Stroe, Van Bockstal, Valenzuela, Ayuso, Leys, Annaert, Carpentier, Smits, Allegaert, Zeltner, Mulder, Van Ginneken and Van Cruchten. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Stroe, Marina-Stefania
Van Bockstal, Lieselotte
Valenzuela, Allan
Ayuso, Miriam
Leys, Karen
Annaert, Pieter
Carpentier, Sebastien
Smits, Anne
Allegaert, Karel
Zeltner, Adrian
Mulder, Antonius
Van Ginneken, Chris
Van Cruchten, Steven
Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps
title Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps
title_full Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps
title_fullStr Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps
title_full_unstemmed Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps
title_short Development of a neonatal Göttingen Minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps
title_sort development of a neonatal göttingen minipig model for dose precision in perinatal asphyxia: technical opportunities, challenges, and potential further steps
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195037/
https://www.ncbi.nlm.nih.gov/pubmed/37215599
http://dx.doi.org/10.3389/fped.2023.1163100
work_keys_str_mv AT stroemarinastefania developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT vanbockstallieselotte developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT valenzuelaallan developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT ayusomiriam developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT leyskaren developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT annaertpieter developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT carpentiersebastien developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT smitsanne developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT allegaertkarel developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT zeltneradrian developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT mulderantonius developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT vanginnekenchris developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps
AT vancruchtensteven developmentofaneonatalgottingenminipigmodelfordoseprecisioninperinatalasphyxiatechnicalopportunitieschallengesandpotentialfurthersteps